Iti-Nova 100 Capsule contains Itraconazole 100 mg, a broad-spectrum antifungal agent belonging to the triazole class. Iti-Nova 100 is indicated for the treatment of various fungal infections including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. Disruption of ergosterol synthesis results in increased membrane permeability and ultimately fungal cell death. The drug is well absorbed orally, with bioavailability enhanced when taken with food. Iti-Nova 100 should be administered as prescribed, with dosage and duration tailored to the type and severity of infection. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea, as well as headache and dizziness. Caution is advised in patients with hepatic impairment, and periodic liver function monitoring is recommended during prolonged therapy. Iti-Nova 100 may interact with several medications metabolized via the cytochrome P450 system; therefore, a thorough review of concomitant drugs is essential to avoid potential interactions. This medication should be used under strict medical supervision.